DOCSLIB.ORG

Effect of Innappropriate Naltrexone Use in a Heroin Misuser S H Boyce,Pararmstrong, J Stevenson

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Innappropriate Naltrexone Use in a Heroin Misuser S H Boyce,Pararmstrong, J Stevenson 381 CASE REPORTS Effect of innappropriate naltrexone use in a heroin misuser S H Boyce,PARArmstrong, J Stevenson ............................................................................................................................. Emerg Med J 2003;20:381–382 Naltrexone is a long acting opioid receptor antagonist Box 1 Side effects of naltrexone use used in controlled opioid withdrawal drug programmes. When taken by an opioid dependent patient an acute • Nausea withdrawal reaction will be precipitated. The case is • Vomiting presented where a known opioid drug misuser inadvert- • Anxiety ently ingested naltrexone in conjunction with heroin result- • Headache ing in severe agitation, requiring heavy sedation followed • Sleep disturbance by general anaesthesia to enable investigation and • Lacrimation management of his clinical condition. • Diarrhoea • Sweating • Muscle/joint pains altrexone is a long acting opioid receptor antagonist used in drug rehabilitation programmes to maintain occurred overnight requiring additional sedation with intra- Nopioid abstinence. However, when consumed in venous midazolam. The following morning he took his own conjunction with an opioid substance, prolonged opioid with- discharge. Retrospectively urine toxicology screen confirmed drawal will be precipitated resulting in unpredictable and life the presence of cannabinoids, benzodiazepines, and opioids. threatening medical consequences. We present a case where a known drug misuser consumed naltrexone in conjunction DISCUSSION with heroin. Naltrexone is a comparatively new medication used in drug rehabilitation programmes to maintain abstinence from CASE REPORT heroin and methadone and prevent relapse in former addicts. A 39 year old man presented to the accident and emergency Naltrexone is a competitive opioid receptor antagonist acting department having taken up to three, 50 mg tablets of at the µ and κ opioid receptors by blocking the euphoric effects naltrexone and having smoked an unknown quantity of of exogenous administered opioids. Naltrexone use is re- heroin. He was known to be an injecting drug user and to suf- stricted to specialist clinics and is initially given orally in doses fer from epilepsy. No other recreational drugs, alcohol, or pre- of 25 mg daily, increasing to 50 mg, with courses of treatment scribed medications were known to have been consumed. On lasting many months. The total weekly dose may be divided arrival he was extremely agitated being restrained by four and given on three days of the week only to improve patient police officers. He was confused, sweating, with episodes of compliance. Oral absorption of naltrexone is rapid with peak profuse projectile diarrhoea and vomiting. Glasgow Coma plasma concentrations occurring after three hours and Scale was 12 (spontaneous eye opening, localising to pain, and remains metabolically active for 24–72 hours, however, the using inappropriate speech). Pupils were dilated but reactive precise pharmacodynamics are not completely understood to light. Heart rate was regular at 180 beats/minute and respi- and large differences in serum concentrations of the drug are ratory rate 40 breaths/minute. Blood pressure, oxygen satura- thought to reflect variable first pass mechanism.1 Side effects tion, blood glucose, and temperature were normal. There was of naltrexone use are outlined in box 1. no evidence of head injury and no history of seizure. Urea, Before being given naltrexone, patients are required to be electrolytes, full blood count, and arterial blood gas measure- opioid free for a period of 7–10 days and undergo a supervised ments were normal. Initial attempts at sedation using a com- naloxone challenge before being accepted into a controlled bination of titrated intravenous midazolam and droperidol detoxification programme. Although the effects of the were unsuccessful. After receiving a total of 20 mg midazolam receptor block are surmountable, addicts are cautioned that and 15 mg droperidol he continued to be confused, agitated, attempts would require large amounts of opioids, which may and increasingly violent. An urgent CT head scan was lead to a fatal overdose.2 Naltrexone has also been adminis- arranged to exclude any intracranial pathology. To expedite tered to addicts, either alone or in combination with clonidine, this he was anaesthetised and ventilated. Rapid sequence under heavy sedation or general anaesthesia, a process known induction of anaesthesia was carried out using 200 mg propo- as ultra rapid opioid detoxification, in an attempt to reduce the fol, and 100 mg suxamethonium. Anaesthesia was maintained immediate symptoms of acute opioid withdrawal and begin a with a propofol infusion and incremental paralysis with atra- maintenance oral naltrexone programme earlier.3 Recent curium. studies have highlighted limited success using naltrexone in CT of his brain was normal. A lumbar puncture was the treatment of longstanding alcoholism by reducing the performed while the patient was still anaesthetised. This alcohol craving in this group.45 showed no abnormality. The patient was extubated four hours Accidental or intentional ingestion of naltrexone in opioid after induction and transferred to the medical high depend- dependent people will result in an acute block of opioid recep- ency unit for observation. Further episodes of agitation tors and precipitate a severe opioid withdrawal reaction. www.emjonline.com 382 Boyce, Armstrong, Stevenson required, however, antiemetics and oral diazepam for agitation Box 2 Management of naltrexone precipitated acute were given. After observation for 24 hours the patient was opioid withdrawal discharged with no adverse effects. • Sedation (benzodiazepines) Conclusion • Antiemetics (metclopropamide) The nature, severity, and duration of naltrexone induced acute • Intravenous fluids opioid withdrawal varies greatly between people and the • Non-opioid analgesia (non-steroidal preparations) clinical course of events is unpredictable. With the trend for • May require antispasmodic agents (hyoscine) more addicts to be treated with naltrexone in the community, • May require general anaesthesia and the possibility that current addicts may see naltrexone as a misguided means to break the cycle of drug dependence, the potential exists for increasing numbers of similar presenta- Symptoms of withdrawal can appear after only five minutes tions. Physicians involved in the emergency care of these following ingestion and may last up to 48 hours. Symptoms patients must be aware of the dramatic clinical course of the include confusion, agitation, hallucinations, sweating, tachy- ingestion of naltrexone in opioid misusers and be prepared to cardia, abdominal pain, and episodes of profuse vomiting manage the complications. and/or diarrhoea, which may result in significant fluid losses. Management is supportive with sedation (benzodiazepines), Contributors antiemetics (metclopropamide), intravenous fluids, and non- Stephen Boyce was involved in the research, overall coordination and opioid analgesia (non-steroidal preparations). Antispasmodic writing of the paper. Peter Armstrong identified the case and contrib- uted to the case report and literature search. James Stevenson was agents (hyoscine) may be required for intestinal cramps. involved in the research and writing of the paper. Both Stephen Boyce Opioid administration has no effect and is potentially danger- and James Stevenson will act as guarantors for the paper. ous. Greater doses of opioids would be required to reverse the receptor block and the resulting respiratory depression may be ..................... deeper and more prolonged. Patients may become extremely Authors’ affiliations agitated and possibly violent requiring restraint, the adminis- SHBoyce,PARArmstrong, J Stevenson, Accident and Emergency tration of heavy sedation, and possibly general anaesthesia Department, Crosshouse Hospital, Kilmarnock, UK (see box 2). Correspondence to: Dr S Boyce, 176 Troon Avenue, Greenhills, East The problem of acute opioid withdrawal precipitated by Kilbride G75 8TJ, UK; [email protected] naltrexone appears to be an increasing problem for physicians. Two case reports have been published in the literature from Accepted for publication 1 March 2002 6 Italy in 1999, where an injecting heroin user and an ex-heroin REFERENCES 7 addict receiving methadone treatment both consumed 1 Ferrari A, Bertolotti M, Dell’Utri A, et al. Serum course of naltrexone and naltrexone. In each case, despite repeated attempts at 6 beta-naltrexone levels during long-term treatment in drug addicts. Drug sedation, both patients exhibited increasing agitation and Alcohol Depend 1998;52:211–20. 2 O’Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification delirium requiring to be anaesthetised with propofol, intu- techniques. JAMA 1998;279:229–34. bated, and ventilated. In each case the patients recovered with 3 Rabinowitz J, Cohen H, Tarrasch R, et al. Compliance to naltrexone no adverse effects. More recently concern regarding this pres- treatment after ultra-rapid opiate detoxification: an open label naturalistic 8 study. Drug Alcohol Depend1997;47:77–86. entation has been voiced in Australia. In this instance drug 4 Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release addicts had inadvertently injected naltrexone intravenously naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin after having been sold the preparation incorrectly as heroin by Exp Res1998;22:1074–9. 5 Croop RS,
Load more

Recommended publications
  • Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the Use of Antiemetics Author(S): Dr Annette Edwards (Chai
    Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the use of Antiemetics Author(s): Dr Annette Edwards (Chair) and Deborah Royle on behalf of the Yorkshire Palliative Medicine Clinical Guidelines Group Overall objective : To provide guidance on the evidence for the use of antiemetics in specialist palliative care. Search Strategy: Search strategy: Medline, Embase and Cinahl databases were searched using the words nausea, vomit$, emesis, antiemetic and drug name. Review Date: March 2008 Competing interests: None declared Disclaimer: These guidelines are the property of the Yorkshire Palliative Medicine Clinical Guidelines Group. They are intended to be used by qualified, specialist palliative care professionals as an information resource. They should be used in the clinical context of each individual patient’s needs. The clinical guidelines group takes no responsibility for any consequences of any actions taken as a result of using these guidelines. Contact Details: Dr Annette Edwards, Macmillan Consultant in Palliative Medicine, Department of Palliative Medicine, Pinderfields General Hospital, Aberford Road, Wakefield, WF1 4DG Tel: 01924 212290 E-mail: [email protected] 1 Introduction: Nausea and vomiting are common symptoms in patients with advanced cancer. A careful history, examination and appropriate investigations may help to infer the pathophysiological mechanism involved. Where possible and clinically appropriate aetiological factors should be corrected. Antiemetics are chosen based on the likely mechanism and the neurotransmitters involved in the emetic pathway. However, a recent systematic review has highlighted that evidence for the management of nausea and vomiting in advanced cancer is sparse. (Glare 2004) The following drug and non-drug treatments were reviewed to assess the strength of evidence for their use as antiemetics with particular emphasis on their use in the palliative care population.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014
    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
    [Show full text]
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com
    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
    [Show full text]
  • Emea/666243/2009
    European Medicines Agency London, 29 October 2009 EMEA/666243/2009 ISSUE NUMBER: 0910 MONTHLY REPORT PHARMACOVIGILANCE WORKING PARTY (PHVWP) OCTOBER 2009 PLENARY MEETING The CHMP Pharmacovigilance Working Party (PhVWP) held its October 2009 plenary meeting on 19-21 October 2009. PhVWP DISCUSSIONS ON SAFETY CONCERNS Below is a summary of the discussions regarding non-centrally authorised medicinal products in accordance with the PhVWP publication policy (see under http://www.emea.europa.eu/htms/human/phv/reports.htm). Positions agreed by the PhVWP for non- centrally authorised products are recommendations to Member States. For safety updates concerning centrally authorised products and products subject to ongoing CHMP procedures, readers are referred to the CHMP Monthly Report (see under http://www.emea.europa.eu/pressoffice/presshome.htm). The PhVWP provides advice on these products to the Committee of Medicinal Products for Human Use (CHMP) upon its request. Antipsychotics - risk of venous thromboembolism (VTE) Identify risk factors for VTE for preventive action before and during treatment with antipsychotics The PhVWP completed their review on the risk of VTE of antipsychotics1. The review was triggered by and based on data from the UK spontaneous adverse drug reactions reporting system and the published literature. The PhVWP carefully considered the data, including the limitations of both information sources, such as the lack of randomised controlled trial data, the heterogeneity of published studies and the potential confounding factors such as sedation and weight gain, commonly present in antipsychotic users. The PhVWP concluded that an association between VTE and antipsychotics cannot be excluded. Distinguishing different risk levels between the various active substances was not possible.
    [Show full text]
  • Perphenazine-151548-PI.Pdf
    PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg , 4 mg, 8mg, and 16 mg Antipsychotic/Antiemetic AA Pharma Inc. DATE OF REVISION: April 12, 2012 1165 Creditsone Road, Unit #1 Vaughan, Ontario L4K 4N7 Control Number: 151548 PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg, 4 mg, 8 mg and 16 mg THERAPEUTIC CLASSIFICATION Antipsychotic/Antiemetic ACTIONS AND CLINICAL PHARMACOLOGY Perphenazine is a piperazine phenothiazine derivative with antipsychotic, antiemetic and weak sedative activity. Perphenazine has actions similar to those of other phenothiazine derivatives but appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions. Perphenazine is well absorbed from the gastrointestinal tract. Onset of action following oral administration is 30 to 40 minutes. Duration of action is 3 to 4 hours. Perphenazine distributes to most body tissues with high concentrations being distributed into liver and spleen. Perphenazine enters the enterohepatic circulation and is excreted chiefly in the feces. INDICATIONS AND CLINICAL USE Perphenazine is indicated in the management of manifestations of psychotic disorders. It is also effective in controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. 1 Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. CONTRAINDICATIONS Should not be administered in the presence of circulatory collapse, altered states of consciousness or comatose states, particularly when these are due to intoxication with central depressant drugs (alcohol, hypnotics, narcotics). It is contraindicated in severely depressed patients, in the presence of blood dyscrasias, liver disease, renal insufficiency, pheochromocytoma, or in patients with severe cardiovascular disorders or a history of hypersensitivity to phenothiazine derivatives.
    [Show full text]
  • A Retrospective Review of the Use and Safety of Droperidol in a Large, High-Risk, Inner-City Emergency Department Patient Populaton
    1402 Chase, Biros · DROPERIDOL USE IN THE ED A Retrospective Review of the Use and Safety of Droperidol in a Large, High-risk, Inner-city Emergency Department Patient Populaton Peter B. Chase, MD, PhD, Michelle H. Biros, MD, MS Abstract Droperidol (DROP) is used in the emergency department teria for high risk. There were 622 pts with head trauma (ED) for sedation, analgesia, and its antiemetic effect. Its (401 with alcohol use), including 47 with computed to- ED safety pro®le has not yet been reported in patients mography (CT) scans positive for brain injury, 64 with (pts). Objectives: To document the use of DROP in high- cocaine use, and 197 with recent or remote seizures (137 risk pts (those with head injury, alcohol or cocaine intox- with alcohol use). Minor AEs such as transient hypoten- ication, and/or remote or recent seizures), and to deter- sion occurred in 96 pts after DROP (73 with alcohol use); mine the number of serious and minor adverse events 20 received intravenous ¯uids, while an additonal 28 pts (AEs)Ðseizures, hypotension, extrapyramidal side ef- (8 with alcohol use) received rescue medications for fects (EPSEs)Ðafter DROP. Methods: The ED database EPSEs. Six possible serious AEs occurred in pts with se- (EmSTAT) was queried to determine who received intra- rious comorbidities; 2 cases of respiratory depression, 3 muscular or intravenous DROP in the ED in 1998; further post-DROP seizures, and 1 cardiac arrest (resuscitated) 11 chart review was done if the patient was considered high hours after DROP in a cocaine-intoxicated pt (normal QT risk for or had experienced an AE.
    [Show full text]
  • Inapsine® (Droperidol) Injection
    INAPSINE- droperidol injection Taylor Pharmaceuticals ---------- INAPSINE® (DROPERIDOL) INJECTION FOR INTRAVENOUS OR INTRAMUSCULAR USE ONLY Rx only WARNING Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving INAPSINE at doses at or below recommended doses. Some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal. Due to its potential for serious proarrhythmic effects and death, INAPSINE should be reserved for use in the treatment of patients who fail to show an acceptable response to other adequate treatments, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs (see Warnings, Adverse Reactions, Contraindications, and Precautions). Cases of QT prolongation and serious arrhythmias (e.g., torsade de pointes) have been reported in patients treated with INAPSINE. Based on these reports, all patients should undergo a 12-lead ECG prior to administration of INAPSINE to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. If there is a prolonged QT interval, INAPSINE should NOT be administered. For patients in whom the potential benefit of INAPSINE treatment is felt to outweigh the risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2 to 3 hours after completing treatment to monitor for arrhythmias. INAPSINE is contraindicated in patients with known or suspected QT prolongation, including patients with congenital long QT syndrome. INAPSINE should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval).
    [Show full text]
  • Droperidol for Psychosis-Induced Aggression Or Agitation
    This is a repository copy of Droperidol for psychosis-induced aggression or agitation. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/158362/ Version: Published Version Article: Khokhar, Mariam Ahmad orcid.org/0000-0002-5556-8301 and Rathbone, John (2016) Droperidol for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews. CD002830. ISSN 1469-493X https://doi.org/10.1002/14651858.CD002830.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Droperidol for psychosis-induced aggression or agitation (Review) Khokhar MA, Rathbone J Khokhar MA, Rathbone J. Droperidol for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No.: CD002830. DOI: 10.1002/14651858.CD002830.pub3. www.cochranelibrary.com Droperidol for psychosis-induced aggression or agitation (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLEOFCONTENTS HEADER....................................... 1 ABSTRACT .....................................
    [Show full text]
  • Drugs Which Can Affect Near Vision: a Useful List
    Drugs Which Can Affect Near Vision: A Useful List Joanne L. Smith B.Sc., Ph.Phm.* J. Raymond Buncic, M.D., F.R.C.S.(C)t ABSTRACT This paper documents a list of drugs that cause problems with near vision, by virtue of effects on accommodation, occasionally refractive error and diplopia. It is meant as a reference aid to the clinician when confronted with problems of focusing on near objects or print. There are many drugs that have been reported to interfere with near or reading vision, producing blurring, decreased accommodation and diplopia. This paper lists the drugs that have been reported in the literature to produce symptoms which interfere with near vision. Case reports for the listed drugs vary greatly from many to few. The drugs have been divided into the following categories: those causing (A) blurring at near, (B) diplopia and (C) induced myopia. Those drugs which only rarely cause these symptoms have been omitted. From the Departments of Pharmacy* and Ophthalmologyt, The Hospital For Sick Children, Toronto, Ontario, Canada Requests for reprints should be addressed to: Dr. J. Raymond Buncic, Department of Ophthalmology, The Hospital For Sick Children, 555 University Ave., Toronto, Ontario, Canada M5G lX8 TABLE 1 DRUGS COMMONLY CAUSING DIFFICULTY WITH FOCUSING AT NEAR OR BLURRED VISION. DRUG INCIDENCE REFERENCE Antipsychotics Chlorpromazine 14-23 8 Clozapine 5 8,14 Fluphenazine 1.2-4.3 8 Haloperidol 6.8-16 8 Loxapine 12,14 Perphenazine 7.4-17.8 8 Pimozide 20 8 Risperidone 1-2%, >/= 10% 11 Thioridazine 0.6-18 8 Thiothixene 20 8
    [Show full text]
  • Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period
    Supplementary Online Content Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naïve patients in the postoperative period. JAMA Intern Med. Published online July 11, 2016. doi:10.1001/jamainternmed.2016.3298. eTable 1. List of CPT Codes eFigure. Sample Construction Flow Chart eTable 2. List of Drug Classes eTable 3. List of Medical Comorbidities and ICD-9 Codes eTable 4. Sample Summary Characteristics, by procedure eTable 5. Risk Factors for Chronic Opioid Use Following Surgery Among Opioid Naïve Patients This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 1. List of CPT codes CPT Codes Total Knee Arthroplasty1 27447 Total Hip Arthroplasty1 27130 Laparoscopic Cholecystectomy2 47562, 47563, 47564 Open Cholecystectomy3 47600, 47605, 47610 Laparoscopic Appendectomy4 44970, 44979 Open Appendectomy5 44950, 44960 Cesarean Section6 59510, 59514, 59515 FESS7 31237, 31240, 31254, 31255, 31256, 31267, 31276, 31287, 31288 Cataract Surgery8 66982, 66983, 66984 TURP9 52601, 52612, 52614 Simple Mastectomy10‐12 19301, 19302, 19303, 19180 © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eFigure. Sample Construction Flow Chart © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 2.
    [Show full text]
  • Package Leaflet: Information for the User
    Package leaflet: Information for the user Xomolix 2.5 mg/ml solution for injection Droperidol Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or nurse. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Xomolix is and what it is used for 2. What you need to know before you are given Xomolix 3. How you will be given Xomolix 4. Possible side effects 5. How to store Xomolix 6. Contents of the pack and other information 1. What Xomolix is and what it is used for Xomolix is a solution for injection containing the active substance droperidol, which belongs to a group of antipsychotics called butyrophenone derivatives. Xomolix is used to prevent you feeling sick (nausea) or vomiting when you wake up after an operation or when you receive morphine based painkillers after an operation. 2. What you need to know before you are given Xomolix You should not be given Xomolix if you: are allergic to droperidol, or any of the other ingredients of this medicine (listed in section 6). are allergic to a group of medicines used to treat psychiatric disorders, called butyrophenones (e.g. haloperidol, triperidol, benperidol, melperone, domperidone) or anyone in your family have an abnormal electrocardiogram (ECG) heart tracing have low levels of
    [Show full text]